IceCure Medical Ltd. has regained compliance with the minimum bid price requirement mandated by the Nasdaq Stock Market LLC, securing the continued listing of its securities. The company received written notification on June 18, 2026, confirming that its stock now meets the $1.00 per share threshold required under Nasdaq Listing Rule 5550(a)(2).

The compliance status addresses a critical regulatory requirement for the developer of minimally-invasive cryoablation technology, which destroys tumors by freezing as an alternative to surgical removal. Nasdaq staff determined compliance after the closing bid price of the company's ordinary shares was $1.00 or greater for 10 consecutive business days from June 4 to June 17, 2026. Consequently, Nasdaq considers the bid price deficiency matter now closed.

Compliance Details

The following table outlines the key compliance parameters met by IceCure Medical:

IceCure Medical develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors by freezing. Its primary focus areas include breast, kidney, bone, and lung cancer. The company's flagship ProSense system is marketed and sold worldwide for indications cleared and approved to date, including in the U.S., Europe, and Asia. The company's common stock trades on the Nasdaq market under the ticker symbol ICCM.

IceCure Medical Ltd. highlighted a newly published peer-reviewed article in the International Journal of Surgery that presents key clinical advantages of cryoablation over radiofrequency ablation (RFA) for early-stage breast cancer. The publication, globally ranked in the top three among surgery journals, emphasizes the growing body of evidence supporting cryoablation as a minimally invasive treatment option, noting procedural benefits such as shorter recovery times and improved cosmetic outcomes compared to breast-conserving surgery (BCS). The announcement comes as the company prepares for the 34th Annual Meeting of the Japanese Breast Cancer Society (JBCS) scheduled for June 25-27, 2026, in Kyoto, Japan.

The article, titled "Thermal Ablation as a Minimally Invasive Alternative to Surgery for Primary Breast Cancer," was authored by Drs. Masato Takahashi, Takayuki Kinoshita, and Eisuke Fukuma. Professor Fukuma, a ProSense user at Kameda Medical Center, has performed an estimated 680 breast cancer cryoablation procedures. The publication evaluates current clinical evidence for cryoablation and RFA as alternatives to BCS, indicating that thermal ablation technologies offer local tumor control rates comparable to surgery for selected patients with small tumors.

Clinical Data Comparison

The study provides a comparative analysis of recurrence-free survival rates between cryoablation and RFA. Data presented at the 2025 JBCS Conference showed a recurrence-free rate of 99.02% from over 600 breast cancer patients treated with cryoablation, with follow-up extending up to 17 years. In contrast, the RAFAELO study on RFA reported a 5-year ipsilateral breast tumor-free survival rate of 98.6% in 353 patients.

Procedural Advantages

The authors outlined several key advantages of cryoablation over RFA. Cryoablation can be performed under local anesthesia, whereas RFA requires general anesthesia. During the procedure, cryoablation allows for flexible adjustment of the ice ball size, and the ice ball margin is visible. RFA is described as harder to control due to tissue resistance, with micro-bubbles only vaguely visible. Multiple studies reviewed found no significant differences in local recurrence or overall survival between thermal ablation and BCS for patients with tumors measuring 2 cm or less.

Regulatory Developments in Japan

Terumo Corporation, IceCure's exclusive distributor in Japan and one of the world's top 20 medical device companies, is expected to submit ProSense for regulatory approval for breast cancer to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in the second half of 2026. The submission will leverage international clinical data and Japanese physician experience. Eyal Shamir, Chief Executive Officer of IceCure, stated that the growing clinical evidence is accelerating physician interest worldwide, particularly following the FDA marketing authorization of ProSense for early-stage breast cancer in October 2025. Japan is identified as a key market for the company's expansion efforts.